UNSPSC 51143405: Belladonna/ergotamine/phenobarbital

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN105. This VA Drug Class (CN105) classifies this compound as belonging to the group ANTIMIGRAINE AGENTS.

UNSPSC 51143405 Belladonna/ergotamine/phenobarbital is a Commodity code that shows a significant mismatch between its nominal pharmaceutical scope and the actual work state and local governments are soliciting under it. Recent opportunities tagged to this code involve naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceutical distribution — none of which involve belladonna, ergotamine, or phenobarbital compounds. The code appears to function as a catch-all pharmaceutical procurement tag rather than a category for the specific drug combinations its name denotes. State and local issuing bodies using this code include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and cooperative purchasing alliances serving multiple states (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, which includes Oregon participants). The work being solicited ranges from direct product procurement — naloxone and drug deactivation systems for community health — to exploratory market-intelligence activities around prescription fulfillment and manufacturer relationships.

Geographic activity centers on Florida, Texas, and the MMCAP multi-state footprint (Minnesota and Oregon named). Recent solicitations include Seminole County's IFB 60459723LAS, posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 (note: deadline date appears erroneous in the source); Texas HHS's RFI HHS0017013, posted April 3, 2026, to gather vendor capabilities on direct-to-manufacturer prescription programs; and MMCAP's RFP S1070000015802, posted January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline, requiring vendors to supply through three authorized wholesalers and achieve product-market availability by May 15, 2026. The Seminole County and MMCAP procurements are active transactional opportunities; the Texas RFI represents early-stage market research without stated budget or formal award timeline. Business development professionals should verify whether this code's actual usage matches their product lines before pursuing opportunities tagged to it.